Romanian Journal of Infectious Diseases Logo
  • Home
  • Aims & Scope
  • Standards
    • Editorial policies
    • Instructions for authors
    • Peer review process
    • Guidelines for Reviewers
    • Ethics and Malpractice policies
    • Official Journal’s protocols & statements
    • Open Access
    • Fees
  • Editorial Council
  • Peer Review Council
  • EMC | CME
  • How to
  • SUBSCRIBE
  • Menu

Arhiva autor

  • About
  • Latest Posts

Laura Elena Iliescu

Latest posts by Laura Elena Iliescu (see all)

  • EVALUAREA NON-INVAZIVA A FIBROZEI HEPATICE CU AJUTORUL ELESTOGRAFIEI HEPATICE (FIBROSCAN) LA PACIENTII CU INFECTIE CRONICA VHB SI VHC - 16/12/2016
  • NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS USING LIVER ELASTOGRAPHY (FIBROSCAN) IN PATIENTS WITH CHRONIC INFECTION HBV AND HCV - 16/12/2016
  • TRATAMENTUL INFECŢIEI CRONICE VHC CU DAA ŞI EVOLUŢIA FIBROZEI HEPATICE ÎN TIMPUL TRATAMENTULUI: EXPERIENŢA UNUI CENTRU - 15/12/2016

Articole semnate de acelasi autor in Revista Romana de Boli Infectioase:

EVALUAREA NON-INVAZIVA A FIBROZEI HEPATICE CU AJUTORUL ELESTOGRAFIEI HEPATICE (FIBROSCAN) LA PACIENTII CU INFECTIE CRONICA VHB SI VHC

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XIX, No. 3, Year 2016
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

EVALUAREA NON-INVAZIVA A FIBROZEI HEPATICE CU AJUTORUL ELESTOGRAFIEI HEPATICE (FIBROSCAN) LA PACIENTII CU INFECTIE CRONICA VHB SI VHC

Andreea Rădășan, Mihai Voiculescu and Laura Elena Iliescu

ABSTRACT

Introduction. In recent years there have been major advances in the treatment and prevention of viral hepatitis, but this pathology is still a major health and socio-economic problem. The defining element for this disease is the liver fibrosis, a histological component of particular importance due to its role in the formation of liver lesions of cirrhosis. Thus, an essential step in the management of chronic viral hepatitis is the detection and measurement of liver fibrosis. Today we have invasive methods for detecting liver fibrosis, the liver puncture biopsy, and non-invasive methods, which in turn are divided into serum methods and imaging methods (2).
Purpose of the Study. The aim of this study is to determine if transcutaneous elastography (FibroScan) is equally reliable in case of viral hepatitis B, as with viral hepatitis C.
Material and Method: The study comprises a total of 1,127 patients with liver disease of HBV and HCV aetiology. These patients were examined using FibroScan in the period July 2009 - April 2011.
Results: Of the 1,177 patients investigated using FibroScan, 40 underwent liver biopsy as well. Of these, 82% have obtained same stages of liver fibrosis in these two investigations, and 18% achieved different stages of fibrosis in these two tests. For the patients with HCV infection, we obtained a 67.81% match of the two non-invasive tests, FibroScan and FibroMax, and a 79.16% match of FibroScan compared to the Liver Biopsy. For the B virus, the compliance is even better, of 75% (FibroScan - FibroMax), and 80% for FibroScan - LB.
Conclusions: FibroScan is one of the non-invasive assessment methods of liver fibrosis with diagnose accuracy similar to FibroMax and close to Liver Biopsy.

Keywords: Hepatitis B, Hepatitis C, FibroScan, FibroMax, Fibrosis, accuracy, match

Full text | PDF

NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS USING LIVER ELASTOGRAPHY (FIBROSCAN) IN PATIENTS WITH CHRONIC INFECTION HBV AND HCV

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XIX, No. 3, Year 2016
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS USING LIVER ELASTOGRAPHY (FIBROSCAN) IN PATIENTS WITH CHRONIC INFECTION HBV AND HCV

Andreea Rădășan, Mihai Voiculescu and Laura Elena Iliescu

ABSTRACT

Introduction. In recent years there have been major advances in the treatment and prevention of viral hepatitis, but this pathology is still a major health and socio-economic problem. The defining element for this disease is the liver fibrosis, a histological component of particular importance due to its role in the formation of liver lesions of cirrhosis. Thus, an essential step in the management of chronic viral hepatitis is the detection and measurement of liver fibrosis. Today we have invasive methods for detecting liver fibrosis, the liver puncture biopsy, and non-invasive methods, which in turn are divided into serum methods and imaging methods (2).
Purpose of the Study. The aim of this study is to determine if transcutaneous elastography (FibroScan) is equally reliable in case of viral hepatitis B, as with viral hepatitis C.
Material and Method: The study comprises a total of 1,127 patients with liver disease of HBV and HCV aetiology. These patients were examined using FibroScan in the period July 2009 - April 2011.
Results: Of the 1,177 patients investigated using FibroScan, 40 underwent liver biopsy as well. Of these, 82% have obtained same stages of liver fibrosis in these two investigations, and 18% achieved different stages of fibrosis in these two tests. For the patients with HCV infection, we obtained a 67.81% match of the two non-invasive tests, FibroScan and FibroMax, and a 79.16% match of FibroScan compared to the Liver Biopsy. For the B virus, the compliance is even better, of 75% (FibroScan - FibroMax), and 80% for FibroScan - LB.
Conclusions: FibroScan is one of the non-invasive assessment methods of liver fibrosis with diagnose accuracy similar to FibroMax and close to Liver Biopsy.

Keywords: Hepatitis B, Hepatitis C, FibroScan, FibroMax, Fibrosis, accuracy, match

Full text | PDF

TRATAMENTUL INFECŢIEI CRONICE VHC CU DAA ŞI EVOLUŢIA FIBROZEI HEPATICE ÎN TIMPUL TRATAMENTULUI: EXPERIENŢA UNUI CENTRU

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XIX, No. 3, Year 2016
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

TRATAMENTUL INFECŢIEI CRONICE VHC CU DAA ŞI EVOLUŢIA FIBROZEI HEPATICE ÎN TIMPUL TRATAMENTULUI: EXPERIENŢA UNUI CENTRU

Andreea Rădășan, Laura Elena Iliescu and Mihai Voiculescu

REZUMAT

Introducere. Hepatita C reprezintă o inflamaţie a ficatului, cauzată de virusul hepatitic C. Virusul C este de aproximativ 10 ori mai infecţios decât virusul HIV. Infecţia acută determina rar simptomatologie şi se poate vindeca spontan în primele 6 luni, la aproximativ 20% dintre pacienţii infectaţi. În cele mai multe cazuri, însă, infecţia devine cronică (până la 80% din cazuri) (6). Hepatita cronică VHC este o cauză majoră de ciroza hepatică şi hepatocarcinom, în întreaga lume (7). În ultimele decenii, tratamentul standard pentru infecţia cronică VHc a fost combinaţia PEG-IFN şi Ribavirina (RBV). Prezentul şi viitorul tratamentului pentru virusul C este reprezentat de noile generaţii de DAA, în general, Exviera+Viekirax pentru România, în special.
Obiectivele studiului: Obiectivul principal al acestui studiu este de a determina cum tolerează pacienţii cu infecţie cronică VHC, cu fibroză hepatică F4, noul tratament cu DAA, precum şi care va fi evoluţia fibrozei hepatice.
Material şi metodă: În acest studiu au fost înrolaţi 33 pacienţi, din Centrul de Medicină Internă, Institutul Clinic Fundeni, internaţi în perioada 02.2016 - 08.2016. Am evaluat sindromul inflamator, sindromul de colestaza şi evoluţia fibrozei hepatice la aceşti pacienţi.
Rezultate: Am observant o reducere semnificativă a sindromului infamator, nivelul bilirubinei serice a înregistrat, de asemenea, o scădere, dar în ceea ce priveşte stadiul fibrozei hepatice, acesta a rămas acelaşi, la
sfârşitul tratamentului antiviral cu DAA, Exviera+Viekirax.
Concluzii: Este nevoie de mai multe date pentru a putea formula o concluzie solidă, în cee ace priveşte rata SVR, efectele secundare, evoluţia fibrozei hepatice şi eventualele recăderi.

Cuvinte cheie: hepatită, infecţie VHC, terapie, fibroză hepatică, evoluţie

Full text | PDF

THE DAAS TREATMENT OF CHRONIC HCV INFECTION AND THE LIVER FIBROSIS EVOLUTION DURING TREATMENT: OUR EXPERIENCE

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XIX, No. 3, Year 2016
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

THE DAAS TREATMENT OF CHRONIC HCV INFECTION AND THE LIVER FIBROSIS EVOLUTION DURING TREATMENT: OUR EXPERIENCE

Andreea Rădășan, Laura Elena Iliescu and Mihai Voiculescu

ABSTRACT

Introduction. Hepatitis C is a liver inflammation caused by hepatitis C virus. HCV is about 10 times as infectious as HIV. The acute infection rarely causes symptoms and can clear up spontaneously in the first six months in about 20% of those affected. In most cases, however, the infection becomes chronic (up to 80%)6. Chronic hepatitis C is a major cause of liver cirrhosis and hepatocellular carcinoma worldwide7. In the past decades, the standard treatment for hepatitis C viral infection was PEG-IFN and ribavirin (RBV). The future for the treatment of chronic hepatitis C infection is represented by DAAs and for Romania, the future is called Exviera+Viekirax.
Objective of the study: The main purpose of the survaillance was to determine how these HCV chronic infection patients with F4 liver fibrosis tolerate the new DAAs treatment and how the liver fibrosis will decrease or increase.
Matherial and methods: The study enrolled 33 patients from Internal Medicine Center, Fundeni Clinical Institute, during the time period 02.2016 – 08.2016. We evaluated the inflammatory syndrome, the cholestatic syndrome and the evolution of liver fibrosis.
Results: We have noticed a significant decrease of inflammatory syndrome, the bilirubin level decreased also, but the stage of liver fibrosis remained the same, at the end of treatment with Eviera+Viekirax.
Conclusions: We had a small experience so far, with Exviera+Viekirax regimen. The patients tolerated very well the therapy and the virological response was 100% for all subjects.

Keywords: hepatitis, HCV infection, therapy, liver fibrosis, evolution

Full text | PDF



SEARCH

STANDARDE

  • Instructions for AUTHORS
  • Peer review process
  • Official Journal’s protocols
  • Pending articles

Submit article

Use this form to submit your article to the editors:

SUBMIT ARTICLE

Subscriptions

To receive the journal, please click here:

SUBSCRIBE

Partners

Conferinta Nationala de Medicina Familiei
Publicare
Abonare

plic-maileditor@rjid.com.ro

Subscribe to the Newsletter

Articles from the journal are licensed under a 
Creative Commons Attribution 4.0 International License

 Terms & Conditions

Open Access Statement

Publisher : AMALTEA Medical Publishing House

The intended audience of the site content is professionals from the medical and pharmaceutical community.
This site does not collect any personal data nor does it use cookies that might obtain such data from your browser. [ info ]
Agree
Contact

Submit ARTICLE
E-mail: editor@rjid.com.ro  |  Mobile: +4 0742.155.512, M-F 09.00-18.00 EET

SUBSCRIPTIONS
E-mail: info@amaltea.ro |  Mobile: +4 0742.155.511, M-F 09.00-18.00 EET